After its last attempt at a merger failed in 2023, Redx Pharma seems to have found a willing partner in Skye Bioscience, which experienced a couple of trial failures in recent years. The public ...
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...
Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs. In its second-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results